Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial.

Tadeusz RobakJerzy BłońskiAleksander Bartłomiej SkotnickiMagdalena PiotrowskaTomasz WróbelJustyna RybkaJanusz KłoczkoŁukasz BołkunBożena Katarzyna BudziszewskaUrszula WalczakAnatoly UssMarta FideckaPiotr Smolewski

Published in: European journal of haematology (2018)

The study confirmed the high efficacy and acceptable safety profile of induction therapy with RCC and maintenance therapy with rituximab in previously untreated patients with CLL.

Keyphrases

chronic lymphocytic leukemia
renal cell carcinoma
clinical trial
low dose
study protocol
randomized controlled trial
diffuse large b cell lymphoma
mesenchymal stem cells
cell therapy